To help address the impact of COPD on patients and communities, global healthcare companies Sanofi and Regeneron are working together to study the ripple effects of COPD and to help create a ...

His research gives me great hope for the future of global health and scientific innovation." Now in its landmark 75 th year, Regeneron ISEF remains the premier global stage for the next generation of ...

Now in its landmark 75 th year, Regeneron ISEF remains the premier global stage for the next generation of scientists and engineers. This milestone year celebrates decades of scientific discovery ...

Yancopoulos Innovator Award at the 75 th Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest pre-college science and engineering competition. The award is named ...

In a high-profile antitrust case, a federal jury in Delaware awarded Regeneron Pharmaceuticals over $405 million in damages, finding that Amgen Inc. illegally stifled competition and disrupted ...

As of May 6, 2025, the average one-year price target for Regeneron Pharmaceuticals is $824.33/share. The forecasts range from a low of $540.35 to a high of $1,063.65.

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Neutral to Buy. There are 2,406 funds or institutions reporting positions in ...

A talented learner from Luhlaza High School in Khayelitsha, Salusiwe Mxayiya is gearing up to represent her country at the esteemed Regeneron International Science and Engineering Fair (ISEF), also ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst ...

Pharmaceutical companies have agreed to pay Hawaii $700 million to settle its lawsuit over the efficacy and safety of the blood thinner Plavix, the state attorney general's office announced Friday.